Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.2001
Schlusskurs vom Vortag:
$0.2001
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$13.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.53M
KGV:
0.00
EPS:
-3.66
Netto-Cashflow:
$-39.93M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$3.10
Unity Biotechnology Inc Stock (UBX) Company Profile
Firmenname
Unity Biotechnology Inc
Sektor
Branche
Telefon
(650) 416-1192
Adresse
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Vergleichen Sie UBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
0.00 | 13.94M | 0 | -52.53M | -39.93M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-16 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-16 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-01-04 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-11-10 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-06-28 | Hochstufung | Citigroup | Sell → Buy |
| 2021-06-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-16 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-08-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-08-17 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-28 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-03-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Eingeleitet | Mizuho | Buy |
| 2018-05-29 | Eingeleitet | Citigroup | Buy |
| 2018-05-29 | Eingeleitet | Goldman | Neutral |
| 2018-05-29 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Unity Biotechnology Inc Aktie (UBX) Neueste Nachrichten
Unity Biotechnology Inc. Stock Analysis and ForecastTriple-digit profit margins - PrintWeekIndia
What drives Unity Biotechnology Inc. stock priceFree Bull & Bear Market Updates - PrintWeekIndia
Published on: 2025-07-25 18:10:37 - Autocar Professional
Why Unity Biotechnology Inc. stock attracts strong analyst attentionHigh Potential Safe Trades - Newser
What analysts say about Unity Biotechnology Inc. stockOverwhelming financial success - PrintWeekIndia
UBX issues 1 share with 600M votes to speed dissolution plan | UBX SEC FilingForm 8-K/A - Stock Titan
Is Unity Biotechnology Inc. a good long term investmentAccelerated wealth building - Autocar Professional
Unity Biotechnology Alters Voting Dynamics with New Stock - TipRanks
How Unity Biotechnology Inc. stock performs during market volatilityFree Stock Movement Tracking - Newser
Diabetic Macular Edema Pipeline 2025: MOA, ROA, FDA-Approved Drugs, And Clinical Trial Progress Assessment By Delveinsight Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotechnology, Novartis - MenaFN
Diabetic Macular Edema Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotechnology, Novartis - The Globe and Mail
What makes Unity Biotechnology Inc. stock price move sharplyFree Access to Investment Community - Newser
Unity Biotechnology, Inc.(NasdaqGS: UBX) dropped from S&P TMI Index - MarketScreener
New Options Listings and Delistings for July 9th: DTCBD, ECG, EMA, UNBX, DTCB, AKYA, UBX - AInvest
Unity Biotechnology Plunges 11.08% Amid Clinical Trial Closure, Nasdaq Delisting - AInvest
Unity Biotechnology stock plunges after Nasdaq delisting notice By Investing.com - Investing.com India
Unity Biotechnology Faces Nasdaq Delisting and Leadership Changes - TipRanks
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution - TradingView
Future of Aging: Longevity & Anti-senescence Therapy Market to Reach $44.2 Billion by 2030 with 6.1% CAGR - newstrail.com
Unity Biotechnology Faces Nasdaq Delisting Notice - TipRanks
Biotech company once valued at $700 million slashes entire workforce - MSN
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews
HC Wainwright Issues Optimistic Forecast for UBX Earnings - Defense World
Unity Biotechnology stock hits 52-week low at $0.66 - Investing.com
Unity Biotechnology stock hits 52-week low at $0.66 By Investing.com - Investing.com India
HC Wainwright & Co. Downgrades Unity Biotechnology (LSE:0YC0) - Nasdaq
Unity Biotechnology (NASDAQ:UBX) Receives Neutral Rating from HC Wainwright - Defense World
Unity Biotech stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com South Africa
Finanzdaten der Unity Biotechnology Inc-Aktie (UBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):